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Discussion
It is not our intention to discuss the causation of tumoral calcinosis. Our information is limited only to the few remarks on the biopsy form sent in with the specimen, and follow-up is impossible under present circumstances. From the data we have, and it should be realized that we deal almost exclusively with Africans, it appears that various ethnic groups-Hamitic, Nilo-Hamitic, and Bantu-have the disease. There is a slight preponderance of females, which is the opposite of Palmer's (1966) findings, and no obvious age limitation from the second decade onwards. As in the previous series, the sites of tumours are near joints. Unlike the cases reported by Palmer (1966) and Thomson (1966) we had none near the shoulder or scapula, which would cast doubt on the thesis that pressure on certain areas during sleep or resting on the ground or on hard beds predisposed to its location there. However, the great preponderance of tumours in " pressure areas " around the hips, with ulceration and even perforation in some cases, cannot be dismissed as pure chance.
Another point of difference in our series is that we have seen occasional bone formation, so that the condition is not quite "the exact reverse of myositis ossificans " as suggested by Thomson (1966) . However, we have no theory to offer regarding its causation.
It is worth mentioning for its negative value that we obtained a sterile specimen from the one case that came to our hospital. No organisms could be grown. At the moment surgical excision is the only effective treatment.
Introduction
When myocardial infarction is accompanied by hypotension and weak or impalpable peripheral pulses, together with pallor, cyanosis, clouding of consciousness, and oliguria, the mortality is greater than 80% (Epstein and Relman, 1949; Cronin et at., 1965) . Many therapeutic regimens have been advocated for this state but none has become generally accepted.
Vasopressors are usually considered to be of little value and even harmful (Lancet, 1966) , though these views are not universally held (Kuhn, 1967) , and it has been suggested that vasodilator drugs be tried instead in view of their beneficial effects in experimental cardiogenic shock, in which it was thought that the resulting fall in peripheral resistance allowed increased cardiac output without any increase in cardiac work (Dietzman et al., 1967 (Oriol and McGregor, 1967) . Arterial blood pH, Pco2, and standard bicarbonate were measured by the method of Astrup et al. (1960) , arterial blood lactate with lactate dehydrogenase (Boehringer), and urine flow by continuous bladder drainage. Phenoxybenzamine 1 mg./kg. estimated body weight was given intravenously in 200 ml. of 5% dextrose in half to two hours (Nickerson, 1962; Wilson et al., 1964) ; a slower rate was adopted for three of the last four cases for reasons which are stated. The effect was judged by continuous clinical observation of the patient's general state, blood pressure, pulse rate and volume, skin temperature and colour, urine flow, central venous pressure, and, when possible, by measurement of cardiac output. At least one of us stayed at the bedside continuously while the drug was being given; alterations of pulse volume and skin temperature were assessed independently by both of us and improvement was discounted unless there was agreement.
Observations
The patients were grouped according to the apparent overall effect of phenoxybenzamine, and are not in chronological order.
Probable Harmful Effect (Cases 1-3) Case 5.-This patient, who had a past history of hypertension and angina, became shocked three days after admission with a myocardial infarct. Shortly after the onset of shock the central venous pressure was -4 cm. of water and cardiac output was 3.1 I./min. (Fig. 2) . During the next six hours he deteriorated, and when seen again was unconscious. The central venous pressure had risen to + 6 cm., and there was severe pulmonary oedema.
Phenoxybenzamrine was begun therefore at a rapid rate, without obtaining a baseline cardiac output, and it produced a rapid fall in central venous pressure to -6 cm. of water accompanied by a fall in blood pressure. The drug was stopped, the central venous pressure being restored with an intravenous infusion given in 100-ml. aliquots of 450 ml. of plasma and 450 ml. of isotonic saline over three-quarters of an hour. In contrast to the foregoing cases, a considerable decrease in rales occurred during phenoxybenzamine administration, and this continued during the infusion of intravenous fluids. A slight increase in pulse volume occurred and secretion of a small amount of urine began, but cardiac output Cardiogenic Shock-Riordan and Walters remained low and unconsciousness persisted. The remainder of the phenoxybenzamine was given without any significant effect.
Though some circulatory improvement appeared to occur in these two cases it never seemed likely to be adequate to ensure survival, and both patients died suddenly when there was no medically qualified observer at the bedside. Both were in asystole when seen, and attempted resuscitation was unsuccessful. Beneficial Effect (Cases 6 and 7)
In these cases phenoxybenzamine was again infused slowly and appeared to produce marked circulatory improvement. Initially they were as severely ill as any of the preceding cases. Case 6 had a previous history of two myocardial infarcts, three episodes of left ventricular failure, and one of severe congestive cardiac failure, all requiring admission to hospital. Shock, which was present from the time of onset of his present attack of infarction, was accompanied by sinus bradycardia of 40/min. Atropine 1 mg. intravenously increased the rate to 56/min. without any other sign of improvement. Case 7 had a past history of angina and pulmonary embolism and six months previously a myocardial infarct. Three weeks before the present attack haemoptysis due to pulmonary infarction occurred.
Phenoxybenzamine produced similar improvement in both cases (Figs. 3 and 4) . A fall in central venous pressure was followed by obvious improvement in pulse volume, skin colour and temperature, mental state, and urine flow, and the arterial pressure gradually rose. Clinically the improvement was maximal after about six hours and was accompanied by increased cardiac output and stroke volume and a fall in arterial blood lactate. Respiratory signs increased in both during phenoxybenzamine administration but were not severe enough for it to be stopped. Case 6, whose chest had been clear, developed wheezing and generalized rhonchi two hours after treatment began. This did not respond to aminophylline 0.5 g. intravenously, but it gradually diminished over the next four hours. Case 7 developed a rise in respiratory rate after one and a half hours, and the rales and rhonchi, which had been present at the lung bases before treatment started, became more widespread, but these signs disappeared as circulatory improvement continued.
Case 6 made a full recovery and was discharged after an uneventful convalescence. Case 7 had two further episodes of shock, which responded to further doses of phenoxybenzamine on each occasion, though similar respiratory signs and an increase in the frequency of ventricular ectopic beats occurred each time during administration of the drug. Six days after the first shock episode, while normotensive, he developed ventricular fibrillation and could not be resuscitated. impressive the most striking feature of the series was the appearance of respiratory signs in six of the seven cases. The severity of these seemed to be related to the rate of administration of phenoxybenzamine (Table II) , and in the first three patients, who received the drug most rapidly, the wheezing and expiratory difficulty were very pronounced and unlike anything we have seen previously in cases of myocardial infarction. These signs suggest bronchospasm, but we know of no evidence that phenoxybenzamine affects bronchial muscle. They might, however, be due to reflex bronchospasm or to mucosal swelling caused by vasodilatation, possibly accentuated by passive congestion. Dilatation and engorgement of mucosal blood vessels was a very prominent finding at necropsy, together with large amounts of mucus in the bronchi in two of the three severe cases. Mild The appearance of wheezing or rhonchi was accompanied by the appearance or worsening of signs of pulmonary oedema, and might therefore be a manifestation of it. Obviously, pulmonary oedema might be due to the disease, but its prominence soon after starting treatment with phenoxybenzamine in six of the seven cases suggests a cause-and-effect relationship. This association was totally unexpected, since phenoxybenzamine has been effective in diminishing pulmonary oedema in other circumstances (Nickerson and Gourzis, 1962) , as indeed it appeared to be in our Case 5. The mechanism by which such an effect could be produced is far from clear, but certain possibilities may be considered.
Phenoxybenzamine will produce a fall in, peripheral resistance, and unless this is accompanied by an equivalent increase in cardiac output the mean arterial pressure will fall, leading to further impairment of coronary artery perfusion; left atrial pressure may then rise sufficiently to cause pulmonary oedema. As it has been shown that sphygmomanometer readings do not reflect intra-arterial pressure accurately in the presence of vasoconstriction (Cohn, 1967) , no definite conclusions can be drawn from our observations on blood-pressure changes. Alternatively, a depressant effect on the myocardium might also produce left ventricular failure ; but phenoxybenzamine does not block the inotropic effect of adrenaline (Nickerson and Chan, 1961) , and we know of no evidence for a direct depressant action.
Alpha-adrenergic blockade, in addition to reducing peripheral resistance, may also affect the pulmonary vascular resistance. Halmngyi et al. (1953) found that alpha-blockade with dibenamine lowered the pulmonary vascular resistance in patients with chronic left heart failure due to various causes, in whom it was raised; the effect on pulmonary resistance preceded that on peripheral resistance. No such effect was produced when the pulmonary vascular resistance was normal in these conditions. Very little is known about the pulmonary vascular resistance in shock due to myocardial infarction, but it may be inferred from recent reports that the pulmonary resistance may be normal (Kirby et al., 1968) or high (Nixon et al., 1968) . The apparently anomalous effect of phenoxybenzamine on pulmonary oedema in shock due to myocardial infarction might therefore be due to differences in pulmonary vascular resistance.
In patients with a normal pulmonary resistance, remaining unaffected by phenoxybenzamine, systemic vasodilatation would result in a shift of blood from the pulmonary to the peripheral vascular bed, and thus reduce the tendency to pulmonary oedema. Conversely, in patients with a raised pulmonary vascular resistance a rapid fall occurring in advance of systemic vasodilatation might produce a rise in left atrial pressure sufficient to precipitate pulmonary oedema before such a shift of blood could occur. In patients with a high pulmonary resistance given phenoxybenzamine slowly the changes might not be so dramatic, and severe pulmonary oedema might be averted by improvement in left ventricular output consequent on the lowered peripheral resistance.
Despite the apparent adverse effects and the fact that only one of the seven patients survived, we believe that this method of treatment is worthy of further investigation. " Shock " is only one mode of death in myocardial infarction, and any treatment directed specifically at this should be assessed, in the first instance, by its effect on shock rather than survival. In this respect our results appear more encouraging, for phenoxybenzamine was effective in a second patient (Case 7, Fig. 4 ) on three occasions, death due to ventricular fibrillation occurring on the sixth day after admission. Furthermore, it seems possible that the adverse effects produced in at least three patients were due to giving phenoxybenzamine too rapidly, though the rate was always within the generally recommended range.
For full evaluation of the benefits and risks of phenoxybenzamine therapy more detailed haemodynamic studies are required. Measurements of peripheral vascular resistance, which is known to vary considerably from case to case in cardiogenic shock, together with pulmonary resistance and left heart pressures, may establish criteria for selecting patients likely to benefit and for avoiding serious adverse effects. Until such studies are forthcoming, phenoxybenzamine should be used with caution in myocardial infarction, and the rate of administration probably should not exceed 0.5 mg. per minute.
